RVNC Company Profile and Key Details
Revance Therapeutics, Inc.
RVNC Stock Price Chart
Stock Price Today
Revance Therapeutics, Inc. (RVNC) stock remained unchanged at $3.64 a share on NASDAQ. The stock opened at $3.63, fluctuating between $3.63 to $3.65 during the session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Company Information
| Employees | 597 |
| Beta | 0.95 |
| Sales or Revenue | $234.04M |
| 5Y Sales Change% | 25.835% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Revance Therapeutics, Inc. (NASDAQ: RVNC) stock price is $3.64 in the last trading session. During the trading session, RVNC stock reached the peak price of $3.65 while $3.63 was the lowest point it dropped to. The percentage change in RVNC stock occurred in the recent session was 0% while the dollar amount for the price change in RVNC stock was -.
The NASDAQ listed RVNC is part of Biotechnology industry that operates in the broader Healthcare sector. Revance Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Jessica Serra
Head of Investor Relations & ESG
Mr. Justin Ford
Senior Vice President of HR & Head of People
Ms. Taryn Conway
Vice President of Marketing
Ms. Jeanie D. Herbert
Senior Director of Investor Relations & Corporation Communications
Mr. Dwight Moxie
Senior Vice President, Gen. Counsel & Corporation Sec.
Mr. Dustin S. Sjuts
Pres
Ms. Azita Nejad
Senior Vice President of Technical Operations
Mr. Tobin C. Schilke
Chief Financial Officer & Principal Accounting Officer
Dr. Conor Gallagher
Head of Medical Affairs & Aesthetics
Mr. Mark J. Foley
Chief Executive Officer & Director
Mr. Aubrey Rankin
Consultant
Ms. Amie Krause
Chief People Officer
RVNC's closing price is 58.26% higher than its 52-week low of $2.30 where as its distance from 52-week high of $7.56 is -51.85%.
Number of RVNC employees currently stands at 597.
Official Website of RVNC is: https://www.revance.com
RVNC could be contacted at phone 615 724 7755 and can also be accessed through its website. RVNC operates from 1222 Demonbreun Street, Nashville, TN 37203, United States.
RVNC stock volume for the day was 2.14M shares. The average number of RVNC shares traded daily for last 3 months was 3.14M.
The market value of RVNC currently stands at $379.98M with its latest stock price at $3.64 and 104.39M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com